The Food and Drug Administration has revised its provider and recipient fact sheets for the Johnson & Johnson COVID-19 vaccine due to reports of immune thrombocytopenia (ITP), a disorder that can cause easy or excessive bruising and bleeding due to very low platelet levels. According to the recipient fact sheet, the chance of ITP is “very low,” with symptoms in most cases occurring within 42 days after vaccination. FDA said it continues to monitor the level of potential excess risk with the Centers for Disease Control and Prevention. Individuals with a history of ITP should discuss the risk with their health care provider and the potential need for platelet monitoring after vaccination, the fact sheets note. 

Related News Articles

Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…